Regeneron Pharma Price Target Maintained With a $1282.00/Share by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,282
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,300
BofA Securities Initiates Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Announces Target Price $805
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharmaceuticals Analyst Ratings
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,183
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharma Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,282
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,250 From $1,240
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,250
Regeneron Pharma Price Target Raised to $1242.00/Share From $1166.00 by Piper Sandler
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230